Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**5,10,15,20-Tetrakis(4-sulfonatophenyl)-21H,23H-porphine (TSPP)** is a synthetic water-soluble porphyrin derivative. It is primarily used as a photosensitizer in photodynamic therapy (PDT), particularly for tumor treatment and theranostics of rheumatoid arthritis. The mechanism of action involves the absorption of light by the porphyrin core to generate reactive oxygen species that can induce cell death in targeted tissues. TSPP is also utilized in bio-imaging applications due to its photophysical properties[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5,10,15,20-Tetrakis(4-sulfonatophenyl)-21H,23H-porphine.